Novedades en la guía de práctica clínica de la Sociedad Europea de Cardiología en dislipemias: el peso de la evidencia

Mach, 2020, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, Eur Heart J, 41, 111, 10.1093/eurheartj/ehz455 Catap año, 2016, 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias, Eur Heart J, 37, 2999, 10.1093/eurheartj/ehw272 Cooney, 2016, Cardiovascular risk estimation in older persons: SCORE OP, Eur J Prev Cardiol, 23, 1093, 10.1177/2047487315588390 Madsen, 2017, Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies, Eur Heart J, 38, 2478, 10.1093/eurheartj/ehx163 Yeboah, 2012, Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals, JAMA, 308, 788, 10.1001/jama.2012.9624 Mortensen, 2018, Statin trials, cardiovascular events, and coronary artery calcification: implications for a trial-based approach to statin therapy in MESA, JACC Cardiovasc Imaging, 11, 221, 10.1016/j.jcmg.2017.01.029 Lin, 2018, Nontraditional risk factors in cardiovascular disease risk assessment: updated evidence report and systematic review for the US Preventive Services Task Force, JAMA, 320, 281, 10.1001/jama.2018.4242 Baber, 2015, Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study, J Am Coll Cardiol, 65, 1065, 10.1016/j.jacc.2015.01.017 Burgess, 2018, European Prospective Investigation Into Cancer and Nutrición-Cardiovascular Disease (EPIC-CVD) Consortium, Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol, 3, 619 Jellinger, 2017, American Association of clínical Endocrinologists and American College of Endocronology guidelines for management of dyslipidemia and prevención of cardiovascular disease, Endocr Pract, 23, 1, 10.4158/EP171764.APPGL Escobar, 2020, Recomendaciones para mejorar el control lipídico. Documento de consenso de la Sociedad Española de Cardiología, Rev Esp Cardiol, 73, 161, 10.1016/j.recesp.2019.07.024 Navarese, 2018, Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis, JAMA, 319, 1566, 10.1001/jama.2018.2525 Fulcher, 2015, Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,0 00 participants in 27 randomised trials, Lancet, 385, 1397, 10.1016/S0140-6736(14)61368-4 Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 Mihaylova, 2012, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, Lancet, 380, 581, 10.1016/S0140-6736(12)60367-5 Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med, 372, 2387, 10.1056/NEJMoa1410489 Sabatine, 2017, Evolocumab and clínical outcomes in patients with cardiovascular disease, N EnglJ Med, 376, 1713, 10.1056/NEJMoa1615664 Schwartz, 2018, Alirocumab and cardiovascular outcomes after acute coronary syndrome, N Engl J Med, 379, 2097, 10.1056/NEJMoa1801174 Giugli año, 2017, Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol : a prespecified analysis of the IMPROVE-IT Trial, JAMA Cardiol, 2, 547, 10.1001/jamacardio.2017.0083 Giugli año, 2017, Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER Trial, Lancet, 390, 1962, 10.1016/S0140-6736(17)32290-0 Sabatine, 2018, Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER, Circulation, 138, 756, 10.1161/CIRCULATIONAHA.118.034309 Bonaca, 2018, Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), Circulation, 137, 338, 10.1161/CIRCULATIONAHA.117.032235 Szarek, 2019, Alirocumab reduces total nonfatal cardiovascular and fatal events: The ODYSSEY OUTCOMES Trial, J Am Coll Cardiol, 73, 387, 10.1016/j.jacc.2018.10.039 Szarek, 2019, Alirocumab reduces total hospitalizations and increases days alive and out of hospital in the ODYSSEY OUTCOMES Trial, Circ Cardiovasc Qual Outcomes, 12, e005858, 10.1161/CIRCOUTCOMES.119.005858 Thanassoulis, 2014, Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a metaanalysis of randomized trials, J Am Heart Assoc, 3, e000759, 10.1161/JAHA.113.000759 Estruch, 2018, Retraction and republication: primary prevención of cardiovascular disease with a mediterranean diet, N Engl J Med, 378, 2441, 10.1056/NEJMc1806491 Barrios, 2017, A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clínical evidence, Atheroscler Suppl, 24, 1, 10.1016/j.atherosclerosissup.2016.10.003 Ministerio de Sanidad, Servicios Sociales e Igualdad. Agencia Española de medicamentos y productos sanitarios. Informe de Posicionamiento Terapéutico de evolocumab (Repatha®) en hipercolesterolemia (V1/03032016). Publicado el 3 de marzo de 2016. Disponible en:https://www.aemps.gob.es/medicamentosUsoHum año / informesPublicos/docs/lPT-evolocumab-repatha.pdf?x17133. Ministerio de Sanidad, Servicios Sociales e Igualdad. Agencia Española de medicamentos y productos sanitarios. lnforme de Posicionamiento Terapéutico de alirocumab (Praluent®) en hipercolesterolemia (V1/22042016). Publicado el 22 de abril de 2016. Disponible en:https://www.aemps.gob.es/medicamentosUsoHum año / informesPublicos/docs/lPT-alirocumab-Praluent-hipercolesterolemia.pdf. Bach, 2019, Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 years or older: a secondary analysis of a randomized clínical trial, JAMA Cardiol, 4, 846, 10.1001/jamacardio.2019.2306 2019, Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials, Lancet, 393, 407, 10.1016/S0140-6736(18)31942-1 APPs Control lipídico. Enhttps://seCardiología.es/publicaciones/apps/11362-control-lipidico. Consultado 17 Ag 2020.